anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a traditional Chinese medicine for treating swelling and aching of gum. The traditional Chinese medicine comprises, by mass, 6-10 parts of katsumade galangal seed, 8-12 parts of Ajuga pantantha Hand. Mazz., 4-8 parts of acanthopanax root, 8-12 parts of asarum forbesii maxim, 2-6 parts of beautiful phyllodium twig and leaf, 8-12 parts of dried venom of toads, 4-8 parts of fructus arctii, 10-14 parts of herb of glabrous sarcandra, 4-8 parts of Rosa davurica Pall., 8-12 parts of common cnidium fruit, 4-8 parts of fiveleaf gynostemma herb, 8-12 parts of water banyan, 4-8 parts of fructus viticis, 8-12 parts of fructus piperis longi, 8-12 parts of white hyacinth bean, 4-8 parts of potentilla chinensis, 8-12 parts of herb of white clover, 4-8 parts of aloe, 8-12 parts of loofah sponge, 4-8 parts of forrest silkvine stem or root, 8-12 parts of Chinese ixora flower, 4-8 parts of Chinese sprangletop, 8-12 parts of leafy parnassia and 4-8 parts of grifola frondosus. The traditional Chinese medicine has effects of clearing heat and removing toxins, relieving edema or abdominal distension through diuresis or purgation, cooling blood and relieving pain, and clearing and activating the channels and collaterals. Through cooperation of the above traditional Chinese medicine raw materials, the traditional Chinese medicine has good effects of treating swelling and aching of gum. In four years, a test on 70 patients proves that the traditional Chinese medicine can effectively treat swelling and aching of gum has an effective rate of 92.86%.
Background: Service Dogs are trained to assist people with disabilities to accomplish tasks which permit the individual to be more functional in their home and social environment. Often the dogs are trained to help in the completion of activities of daily living and instrumental activities of daily living. Service Dogs are efficacious for individuals with disabilities, such as vision limitations, spinal cord injury and hearing problems. In addition, some mental health outcomes have improved with the introduction of a Service Dog. A research study was mandated in the Department of Defense Bill of 2010, to examine the efficacy of service dogs for Veterans with Post Traumatic Stress Disorder (PTSD). Together with the Cooperative Studies Program, the proponents have designed a research study to effectively meet the demands of the Bill and to provide timely research into an evolving field.

Study Primary Objective: To examine how limitations on activity and quality of life in Veterans with PTSD are impacted by the provision of a Service Dog versus an Emotional Support Dog.

Study Design: A prospective randomized study is proposed which has two randomized arms. Arm one of the study will be Veterans (n=110) randomized and paired with a Service Dog, which has been trained in 5 PTSD-specific tasks to assist with the Veteran's PTSD issues. Arm two (n=110) of the study will be Veterans randomized and paired with an Emotional Support Dog (a dog that provides support via emotional comfort). All Veterans, after confirmation of eligibility, will be randomized to receive a Service Dog or Emotional Support Dog and will be observed for a minimum of three months prior to receiving their dog. During this observation period, Veterans will be required to participate in a Dog Care Course to ensure they are aware of the demands dogs place on humans. Once a dog becomes available, the Veteran will be paired with a Service Dog or Emotional Support Dog. Pairing is the training process in which the Veteran is given instruction and practice in commanding and caring for their new service dog or emotional support dog. The pairing process for a service dog takes place at the contracted dog vendor's location; the pairing process for an emotional support dog takes place at the Veteran's home, facilitated by a VA Dog Trainer. Follow-up with the Veteran begins one week post pairing to track any dog behavior issues, and will continue after pairing for 18 months. Primary outcomes to be examined include limitations on Veteran activity (as measured by the WHO-DAS 2.0) and quality of life (measured by the VR-12). Secondary outcomes include PTSD symptoms (measured by the PCL-5), suicidal ideation (C-SSRS); depression (PHQ-9) and Sleep (PSQI). In addition, health care utilization, anger management (DAR), employment, and work productivity will also be examined. Study outcomes are assessed at baseline (prior to randomization), and at 3-month intervals after a Veteran is paired with a dog until 18 months post pairing. This multi-site study will be conducted at three locations nationwide.
The patients randomized to the control group received no training but are offered the chance to participate in the supervised training after they have completed their antineoplastic treatment, at least after twelve weeks. Patients in early 2nd line treatment ("switch maintenance") will be offered training after 12 weeks, although they have not completed chemotherapy.
PCT No. PCT/US94/04762 Sec. 371 Date Nov. 27, 1996 Sec. 102(e) Date Nov. 27, 1996 PCT Filed Apr. 29, 1994 PCT Pub. No. WO94/25056 PCT Pub. Date Nov. 10, 1994The present invention provides a non-invasive method for improving collateral circulation to tissue at risk of ischemia or ischemic necrosis. Improved collateral circulation is obtained by applying a growth factor from the PDGF family to the area at or around an occluded blood vessel causing compromised direct circulation to the affected tissue. The present invention further provides a method for anastomosing one or more divided blood vessels using a growth factor from the PDGF family. Preferably, the growth factor is administered locally to the end(s) of the divided blood vessel(s) at or around the area where a single divided blood vessel is attached to tissue of an organ at risk of ischemia.
The invention relates to the technical field of biological medicine. The invention provides a recombinant trivalent multi-epitope oral vaccine based on GEM particles and a preparation method and application thereof, wherein the nucleotide sequence is shown as SEQ ID NO. 1. The invention connects the echinococcosis vaccine gene sequence into the expression vector, and then the expression vector expresses the fusion protein. After the protein is purified by Ni-NTA affinity chromatography, the multi-room echinococcosis vaccine is obtained, and the recombinant antigen SAM-LEE is displayed on the surface of GEM particles by a GEM particle surface display technology, so that the AE oral GEM particle vaccine is constructed. The multi-room echinococcosis GEM particle oral vaccine prepared by the invention has simple operation and low cost, can stimulate organisms to generate specific mucosal immunity aiming at the multi-room echinococcosis, and prevents intermediate hosts and final hosts from infecting the multi-room echinococcosis, thereby controlling the occurrence of the multi-room echinococcosis.
Temporallobe epilepsy (TLE) has been conceptualized as a brain network disease, which generates brain connectivity dynamics within and beyond the temporal lobe structures in seizures. The hippocampus is a representative epileptogenic focus in TLE. Understanding the causal connectivity in terms of brain network during seizures is crucial in revealing the triggering mechanism of epileptic seizures originating from the hippocampus (HPC) spread to the lateral temporal cortex (LTC) by ictal electrocorticogram (ECoG), particularly in high-frequency oscillations (HFOs) bands. In this study, we proposed the unified-epoch dynamic causality analysis method to investigate the causal influence dynamics between two brain regions (HPC and LTC) at interictal and ictal phases in the frequency range of 1-500 Hz by introducing the phase transfer entropy (PTE) out/in-ratio and sliding window. We also proposed PTE-based machine learning algorithms to identify epileptogenic zone (EZ). Nine patients with a total of 26 seizures were included in this study. We hypothesized that: 1) HPC is the focus with the stronger causal connectivity than that in LTC in the ictal state at gamma and HFOs bands. 2) Causal connectivity in the ictal phase shows significant changes compared to that in the interictal phase. 3) The PTE out/in-ratio in the HFOs band can identify the EZ with the best prediction performance.
Breast tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the patient will be separated from peripheral blood. After making them potential cancer killer γδ T Cell, they will be infused to the patients as an immunotherapy treatment NOTE: Originally, our designed proposal was to use autologous PBMCs from cancer patients to ex vivo expand Vγ9Vδ2-T cells, and then perform adoptive transfer therapy. However, PBMCs of majority of cancer patients could not be effectively expanded, including cell number, cell purity and cell function could not meet the requirements of reinfusion. Meanwhile, those patients could not tolerate 100ml of blood drawing for culture every 2 \~ 3 weeks.

Therefore, we submitted new clinical study application to the ethical committee of the Fuda Hospital affiliated with Jinan University (Guangzhou, PR. China) by changing the autologous protocol with the allogeneic protocol. After the allogeneic protocol was approved, we adapted allogeneic cells instead of autologous in our subsequentially clinical study.
After completing the inpatient care (at discharge), the patients randomly assigned to the experimental condition will receive the TAU + CBT4CBT a web-based treatment which has been tested on individuals with cocaine use disorder in America by the team of Dr. K.M. Carroll.
SLE is a chronic, inflammatory autoimmune disorder that may affect many organ systems, including the skin, joints, and internal organs. RG2077 has been studied for use in multiple sclerosis, another autoimmune disorder. This study will evaluate the safety and efficacy of RG2077 in SLE patients who are currently receiving cyclophosphamide.

This trial is composed of two parts. The first part is a dose-escalation study in which participants will receive one of two doses of RG2077 (0.2 mg/kg or 2 mg/kg); this part of the study will last 60 days. At screening, patients will have an IV catheter inserted into their arms for administration of cyclophosphamide and RG2077. Patients will also have medical and medication history assessments, a comprehensive physical exam, and blood and urine tests. There are 5 study visits for the first part of the trial; these will occur at screening, at study entry, and Days 1, 14, and 28. Selected visits will include physical exam, vital signs measurement, blood and urine tests, and disease activity assessment. At Days 7 and 60, patients will be contacted by phone to report their medication history and any adverse effects they have experienced.

The second part of the study will evaluate a single 10 mg/kg dose of RG2077; this part of the study will last 90 days. In the study, participants will be randomly assigned to one of two groups. At the start of the study, Group 1 participants will receive RG2077 and cyclophosphamide and Group 2 participants will receive cyclophosphamide only. There will be 9 study visits; these will occur at study screening, study entry, and Days 1, 4, 7, 14, 28, and 60. At selected visits, patients will undergo physical exam, vital signs measurement, blood tests and urine tests, and disease activity assessment.
Phase I portion of the study, a standard 3+3 dose escalation schema will be followed. Patients will receive veltuzumab IV weekly on day 1 for 4 doses and milatuzumab weekly on for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab alone on day 1 and milatuzumab alone on day 2 to prevent overlapping infusion reactions. Starting week 2, veltuzumab will be given on day 1 and milatuzumab will be given on day 4.
The objective of this randomized clinical trial is to evaluate the efficacy of heparin alone vs compared to combination therapy of Heparin-Aspirin in enhancing free flap survival in patients undergoing reconstructive surgery. Participants will be randomly assigned to one of two groups: one receiving standard heparin therapy and the other receiving a combination therapy that includes heparin and other agents. The primary outcome will be the survival rate of the free flap, assessed at multiple intervals after surgery. Secondary outcomes will to assess the incidence of flap thrombosis, bleeding complications, re-operation in free flap surgeries and overall patient outcomes in both groups. Ethical approval will be obtained, and informed consent will be required from all participants. This trial seeks to provide robust evidence on the potential benefits of combination therapy over heparin alone in free flap survival, potentially informing future clinical guidelines.
The specific aim of this study is to determine preliminarily the efficacy of the AMES intervention in helping older adults quickly readjust their posture in order to recover from unexpected loss of equilibrium. An AMES device will be placed into operation at the University of Arkansas for Medical Sciences (UAMS) Out-patient Rehabilitation Therapy Clinic at Fayetteville, Arkansas(AR), where we will recruit 20 healthy, but near-frail subjects. Ten of these participants will be randomly assigned to a treatment group, and the other 10 will be assigned into a control group that will not receive the AMES intervention. Before and after 12 weeks of training with the bipedal AMES device, ankle strength, range of motion, proprioception, and reaction time, as well as gait and whole-body stability following unexpected balance perturbations will be assessed. In addition to measuring sensorimotor impairment and static balance equilibrium,the incidence of falls in all 20 participants beginning with enrollment into the study for a total of 6 months will be tracked. A reduction in sensorimotor impairment, an improvement in dynamic balance, and a reduction in fall incidence in the treatment group, but not in the control group is expected.
For patients who did not respond to citalopram, open treatment 8 week flexible dosing schedule starting with venlafaxine 37.5mg/day for the first week, then 75mg/day for the second week, then 150mg/day for the third and fourth week, then 225mg/day for the fifth through eighth weeks. At the end of the eighth week, we will assess patients for antidepressant response. At this time-point, venlafaxine responders will be randomized to add-on donepezil or placebo.
Up to now, IMP321 is solely administered by sub-cutaneous injection (e.g. on the anterior face of the thigh). In this study, we investigate whether a direct injection of IMP321 into the tumor tissue will be a useful option to improve anti-tumor immune response by placing the immune-therapeutic agent in direct vicinity of immune infiltrates in the tumor bed. This bypasses processes necessary for drug delivery to cells of solid tumors following systemic administration, like transport within vessels, transport across vasculature walls into surrounding tissues, and - in cases of peritoneal metastases - transport through the interstitial space within a tumor. For the latter case, we will also explore if an intra-peritoneal therapy represents a feasible alternative by means of delivering high drug concentrations directly to tumors located in the peritoneal cavity.

Furthermore, we will explore the possibility to extend the positive results obtained by subcutaneous injections of IMP321 in metastatic renal cell and breast carcinomas to further solid tumor entities. In this part of the study, patients will be treated with the standard-of-care (SOC) chemotherapy and/or immunotherapy/targeted therapy for their tumor entity along with subcutaneous injections of IMP321.
As this is a survey experiment, the "intervention" involves random assignment to a survey questionnaire with specific wording. The first version of the questionnaire includes 6 sets of 3 true-false statements that are innocuous and contextually applicable (e.g., weather, cultural norms) such that there is a low likelihood that the participant will answer untruthfully. The statements on food and water insecurity that are included in the experimental version are omitted.
Transgenic animals that do not express functional SR-BI and ApoE develop severe atherosclerosis, by age four weeks in transgenic mice. Moreover, these animals exhibit progressive heart block by age four weeks, and die by age nine weeks. Pathology shows extensive fibrosis of the heart and occlusion of coronary arteries. The occlusion appears to be due to clotting, since fat deposition is in the walls. These animals are good models for the following diseases, and for screening of drugs useful in the treatment and/or prevention of these disorders: cardiac fibrosis, myocardial infarction, defects in electrical conductance, atherosclerosis, unstable plaque, and stroke. In contrast to other known models for atherosclerosis, these animals do not have to be fed extreme diets for long periods before developing atherosclerosis. No other known model for heart attacks and stroke is known.
DO NOT USE BSS PLUS solution UNTIL PART I IS FULLY RECONSTITUTED WITH PART II. Discard unused contents. BSS PLUS does not contain a preservative; therefore, do not use this container for more than one patient. DISCARD ANY UNUSED PORTION SIX HOURS AFTER PREPARATION. Studies suggest that intraocular irrigating solutions which are iso-osmotic with normal aqueous fluids should be used with caution in diabetic patients undergoing vitrectomy since intraoperative lens changes have been observed.  
  
There have been reports of corneal clouding or edema following ocular surgery in which BSS PLUS solution was used as an irrigating solution. As in all surgical procedures appropriate measures should be taken to minimize trauma to the cornea and other ocular tissues.
The invention discloses a maca solid drink and a preparing method thereof. The drink is prepared from, by mass, maca aqueous extract powder which makes total protein content 4.5-7.0%, 4.0-7.0% of maca essential oil which makes the mass percentage content of macamides in the solid drink 0.1-0.5%, and the balance auxiliary materials. The solid drink particles are 20-50-mesh pellets. During preparation, the powdery auxiliary materials are evenly mixed with the maca aqueous extract powder, 80-85% of edible alcohol is used as a binder, the mixed powder is made into pellets, and after low-temperature drying, the maca essential oil is evenly sprayed into the pellets so that the maca solid drink is obtained. The maca solid drink is simple in compatibility, safe in preparation and free of pollution. The maca aqueous extract and oil-soluble effective constituents are fully combined, product quality and effectiveness are guaranteed, and fatigue resistance can be effectively achieved.
The invention discloses snow pear tablets with auxiliary treatment effect on cough. The snow pear tablets with auxiliary treatment effect on cough are prepared from the following raw materials in parts by mass: 30-50 parts of snow pear fruits, 50-70 parts of milk, 10-20 parts of edible sugar, 10-15 parts of dried orange peel, 10-15 parts of bupleurum, 5-10 parts of fresh gingers, and 20-30 parts of starch. The raw materials used for preparing the snow pear tablets are supplementary to each other, so that the prepared snow pear tablets have the effects of reinforcing and strengthening the body, and are capable of very well relieving the symptoms of weakness and lack of strength caused by coughing. Traditional Chinese medicines with the effects of clearing away lung-heat, reducing phlegm and stopping coughing are mainly utilized, and fruits beneficial for human body are used as auxiliary materials; thus, the prepared snow pear tablets treat both the symptoms and the root causes from the view point of the traditional Chinese medicine. The snow pear tablets has good treatment effect on cough, and is short in treatment course and free of toxic and side effects. The raw materials provided by the invention are reasonable in compatibility and mild in properties, and cause less burden on human body; thus, the prepared snow pear tablets are suitable for a wide range of people to use.
Subjects will receive adalimumab for 24 weeks and will then receive bimekizumab dose regimen 1 until week 56. Subjects will receive placebo at pre-specified time-points to maintain the blinding.
Dantrolene sodium capsules, 25 mg – Capsules with rich yellow opaque bodies and light green opaque caps. Each cap and body imprinted in black with G441.   
Overbagged with 10 capsules per bag, NDC 55154-7140-0.

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Protect from moisture and humidity.

FOR YOUR PROTECTION: Do not use if blister is torn or broken.
Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
PURPOSE:To reduce the sweet taste of glycyrrhizin without reducing its medical effect by including glycyrrhizin in cyclodextrin(CD). CONSTITUTION:In combination with >=0.1 pts.wt. CD (Especially gamma-CD is preferable), 1 pt.wt. glycyrrhizin is used so as to be included in CD. Glycyrrhizing is mixed with CD in water in advance so as to convert the whole part or a part thereof into a substantially sweetless inclusion compound and the resultant inclusion compound may be supplied for use. As another way of use, glycyrrhizin and CD may be blended together with other way materials on the way of production of a drug, a functional food, etc., containing glycyrrhizing so as to form an inclusion compound in that process.
Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
This is a double-blind (test or experiment in which neither the person giving the treatment nor the patient knows which treatment the patient is receiving), placebo-controlled, randomized (study medication assigned to participants by chance) and single-center study of JNJ-63623872. The duration of study will be approximately 5.5 weeks for each ISO per participant. The study consists of 3 parts: Screening Phase (28 days before study commences on Day 1); double-blind Treatment Phase (single oral dose of JNJ-63623872 or placebo on Day 1 under fasted condition); and Follow up Phase (up to 7-10 days after study drug administration). All the eligible participants will be randomly assigned to 1 of 3 groups. The planned doses will be escalated in a stepwise fashion if the safety and tolerability in the preceding dose is found acceptable. Participants in Group 1 will receive JNJ-63623872 300 milligram (mg) or placebo, Group 2 will receive JNJ-63623872 600 mg or placebo and Group 3 will receive JNJ-63623872 1200 mg or placebo. Study drug will be administered following a 10-hour overnight fast. Blood samples will be collected for evaluation of pharmacokinetics at pre-dose and post-dose of study treatment. Pharmacokinetics of JNJ-63623872 will be evaluated primarily. Participants' safety will be monitored throughout the study.